This review examines several of the recently introduced wound care products
that have been put forward as treatment modalities for the diabetic foot u
lcer. Discussed are the results of clinical trials with the platelet-derive
d growth factor, becaplermin, the tissue-engineered products Dermagraft and
Apligraf, and Hyaff which is an ester of hyaluronic acid. In patients with
an infected foot ulcer, encouraging results were obtained with the granulo
cyte-colony stimulating factor, Filgrastim. Copyright (C) 2000 John Wiley &
Sons, Ltd.